Axsome
Manufacturing · New York, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
1 World Trade Ctr Fl 29, New York, New Y...Phone Number
(866) 496-2976Website
www.axsome.comRevenue
$776.6 MillionStock Symbol
AXSMIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
2
2
1
1
1
About Axsome
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are intensely committed to developing products that meaningfully improve the lives of patients and provide additional therapeutic options for physicians.Explore more
Axsome Org Chart
SO
Senior VP, Quality
MB
Vice President, Clinical Development
DC
Vice President, Clinical Development
RN
Vice President, Clinical & Regulatory
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Axsome your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Axsome, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Axsome
Click to see if Axsome had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Axsome is spiking on competitors!
Funding: Get notified immidiatlly once Axsome has new funding data
Check if Axsome has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Axsome launches new products
Earning: See what the market has to say on Axsome recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Axsome
Compare insights from companies similar to Axsome, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Axsome is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Axsome is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Axsome.
Axsome financials insights
Gather financial insights about Axsome, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Debt
$3.7M
2014
Debt
$2M
Debt
$1.3M
2015
Debt
$2.5M
Stock Offering
$51M
2016
Debt
$20M
2025
Debt
$570M
Axsome Tech Stack
A closer look at the technologies used by Axsome
Most Recent Scoops
Open Position
Project
Axsome has announced the launch of AUVELITY in the Alzheimer's disease agitation indication, alongside the completion of an expanded AUVELITY sales force. Early metrics from the sales force expansion and the Alzheimer's disease agitation launch indicate growth acceleration for AUVELITY.
Open Position
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Axsome News & Media
Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction
Axsome Therapeutics (NASDAQ:AXSM) executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in Alzheimer’s disease agitation, while management expects operating expenses to remain relatively stable in theAxsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference
Axsome Therapeutics (NASDAQ:AXSM) executives highlighted growth across its commercial portfolio, an expanded sales force and multiple late-stage clinical programs during the H.C. Wainwright 28th Annual Global Investment Conference. Chief Operating Officer Mark Jacobson said the company has three maAnalysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy?
Or are its best days in the rearview mirror?Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
One company is growing a commercial drug business with limited margin for error on the path to profitability. The other has a platform that proved itself at global scale and keeps finding new diseases to target.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Axsome
Sign Up For FreeTo access detailed company insights
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are intensely committed to develop... Read More
